Completed
PHASE2
INTERVENTIONAL
NCT00395044
Gabapentin Treatment of Cannabis Dependence
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.
Detailed Description
This is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the efficacy of gabapentin in treating outpatients with cannabis dependence. Counseling and research assessments occur weekly throughout the 12-week treatment phase.
Interventions
Name:
Placebo
Type:
DRUG
Description:
Placebo
Name:
Gabapentin
Type:
DRUG
Description:
Primary Outcomes
Measure:
Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12
TimeFrame:
Week 0 and Week 12
Description:
Urinary THC/Cr ratio, also known as CN-THCCOOH (creatinine normalized tetrahydrocannabinol carboxylic acid), is a highly sensitive and specific quantitative analytic procedure to determine current marijuana metabolite levels in the urine as well as new marijuana use or abstinence. Gas chromatography-mass spectrometric levels of 11-nor-9-carboxy-9-THC (THC-COOH), the primary marijuana metabolite, are normalized to the urine creatinine (CN) concentration to reduce the variability of drug measurement attributable to urine dilution. Negative values indicate decreased use.
Trial Information
NCT ID
NCT00395044
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
The Scripps Research Institute
Last Updated
December 15, 2025